Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - A report from the Japanese Diastolic Heart Failure Study (J-DHF)

Journal of Cardiology

Volumn 63, Issue 6, 2014, Pages 424-431

  Yamamoto, Kazuhiro ^a   Origasa, Hideki ^b   Suzuki, Yasushi ^c   Takahashi, Toshiaki ^d   Shinozaki, Tsuyoshi ^e   Watanabe, Tomoyuki ^f   Sakata, Yasushi ^g   Izumi, Chisato ^h   Taira, Kayano ⁱ   Hori, Masatsugu ^j   Sakata, Y ^g   Yamaguchi, O ^g   Mano, T ^g   Kinugawa, K ^k   Oki, T ^l   Oishi, Y ^l   Ishikawa, K ^m,an   Ito, H ⁿ   Kosaka, T ⁿ   Izumi, T ^o   Inomata, T ^o   Fujii, K ^p   Yoshikawa, T ^q   Onishi, K ^r   Maejima, Y ^s   Isobe, M ^s   Nakamura, T ^t   Takahashi, T ^d,ar   Yasumura, Y ^u   Nishigaki, K ^v   Ueda, Y ^w   Kashiwase, K ^w   Tomo hiro, Y ^x   Suzuki, Y ^y   Yoshida, J ^z   Nariyama, J ^aa   Yuda, S ^ab   Kawagoe, T ^ac   Matsuzaki, M ^ad   Yano, M ^ad   Yamamoto, T ^ad   Tsutsui, H ^ae   Okamoto, H ^ae   Goto, D ^ae   Souma, T ^ae   Kijima, Y ^af   Iwahashi, N ^ag   Ebina, T ^ag   Kimura, K ^ag   Nakamura, R ^ah   Okamoto, M ^ai   Yamasaki, N ^aj   Ishikawa, S ^ak   Kajiya, T ^al   Ikeda, Y ^al   Hoshida, S ^am   Kusano, K ^ao   Nakagawa, Y ^h   Izumi, C ^h   Yasumori, K ^ap   Nishino, M ^aq   Yamaguchi, H ^aq   Maruyama, N ^as   Abe, H ^at   Yasuoka, Y ^at   Node, K ^au   Morita, H ^av   Uematsu, M ^aw   Fujita, M ^aw   Watanabe, T ^f,ax   Ono, S ^ay   Saito, Y ^az   Horii, M ^az   Taira, K ⁱ   Shinozaki, T ^e   Yamamoto, H ^ba   Tadehara, F ^ba   Kuwahara, M ^bb   Ohte, N ^bc   Takeda, Y ^bc   Yamamoto, K ^bd   more..

^a TOTTORI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c Department of Orthopaedic Surgery   (Japan)

^d Hiraka General Hospital   (Japan)

^e SENDAI CITY MEDICAL CENTER   (Japan)

^f Watari Hospital   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h TENRI HOSPITAL   (Japan)

ⁱ Yonezawa City Hospital   (Japan)

^j OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l National Hospital Organization   (Japan)

^m Kashiwara Municipal Hospital   (Japan)

ⁿ AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^o KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p Sakurabashi Watanabe Hospital   (Japan)

^q KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^s TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^t Tokyo Medical and Dental University ^*  (Japan)

^u OSAKA NATIONAL HOSPITAL   (Japan)

^v GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^w OSAKA POLICE HOSPITAL   (Japan)

^x Kure kyosai Hospital   (Japan)

^y Department of Surgery   (Japan)

^z Department of Oral Surgery   (Japan)

^aa WEST JAPAN RAILWAY COMPANY   (Japan)

^ab SAPPORO MEDICAL UNIVERSITY   (Japan)

^ac HIROSHIMA CITY HOSPITAL   (Japan)

^ad YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ae HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^af OSAKA CITY GENERAL HOSPITAL   (Japan)

^ag YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^ah SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^ai HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^aj KOCHI MEDICAL SCHOOL   (Japan)

^ak Tsunan Metropolitan Hospital   (Japan)

^al Hyogo Brain and Heart Center   (Japan)

^am Yao Municipal Hospital   (Japan)

^an Fukushima Med ical University   (Japan)

^ao OKAYAMA UNIVERSITY   (Japan)

^ap Seisyukai Clinic   (Japan)

^aq OSAKA ROSAI HOSPITAL   (Japan)

^ar JR Tokyo General Hospital   (Japan)

^as Mitsugi Hospital   (Japan)

^at MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^au SAGA UNIVERSITY   (Japan)

^av Kaizuka City Hospital   (Japan)

^aw KANSAI ROSAI HOSPITAL   (Japan)

^ax YAMAGATA UNIVERSITY   (Japan)

^ay Yamaguchi Saiseikai Hospital   (Japan)

^az NARA MEDICAL UNIVERSITY   (Japan)

^ba HIROSHIMA UNIVERSITY   (Japan)

^bb Tosa Municipal Hospital   (Japan)

^bc NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^bd TOTTORI UNIVERSITY   (Japan)

more..

Author keywords

Diastole; Heart failure; Left atrium; Blocker

Indexed keywords

CARVEDILOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

AGED; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CLINICAL EVALUATION; CLINICAL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HAZARD RATIO; HEART ATRIUM ENLARGEMENT; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT ATRIUM; HOSPITALIZATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; HEART ATRIUM; HEART FAILURE, DIASTOLIC; HEART STROKE VOLUME; LESIONS AND DEFECTS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARBAZOLES; DIABETES MELLITUS; DILATATION, PATHOLOGIC; FEMALE; HEART ATRIA; HEART FAILURE, DIASTOLIC; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROPANOLAMINES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84902199357     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.10.014     Document Type: Article

References (30)

1. Tsuchihashi-Makaya M., Hamaguchi S., Kinugawa S., Yokota T., Goto D., Yokoshiki H., Kato N., Takeshita A., Tsutsui H. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction - a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009, 73:1893-1900.
2. Lam C.S., Donal E., Kraigher-Krainer E., Vasan R.S. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011, 13:18-28.
3. Yamamoto K., Origasa H., Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013, 15:110-118.
4. Rationale and design of a randomized trial to assess the effects of beta-blocker in diastolic heart failure: Japanese Diastolic Heart Failure Study (J-DHF). J Card Fail 2005, 11:542-547. The J-DHF Program Committee.
5. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
6. Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Gong Y., Liu P.P. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.
7. Kenchaiah S., Pocock S.J., Wang D., Finn P.V., Zornoff L.A., Skali H., Pfeffer M.A., Yusuf S., Swedberg K., Michelson E.L., Granger C.B., McMurray J.J., Solomon S.D. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007, 116:627-636.
8. Zile M.R., Gottdiener J.S., Hetzel S.J., McMurray J.J., Komajda M., McKelvie R., Baicu C.F., Massie B.M., Carson P.E. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011, 124:2491-2501.
9. Cleland J.G., Taylor J., Freemantle N., Goode K.M., Rigby A.S., Tendera M. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail 2012, 14:487-494.
10. Hamaguchi S., Kinugawa S., Sobirin M.A., Goto D., Tsuchihashi-Makaya M., Yamada S., Yokoshiki H., Tsutsui H. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J 2012, 76:1662-1669.
11. Curtis J.P., Selter J.G., Wang Y., Rathore S.S., Jovin I.S., Jadbabaie F., Kosiborod M., Portnay E.L., Sokol S.I., Bader F., Krumholz H.M. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005, 165:55-61.
12. Nishio M., Sakata Y., Mano T., Ohtani T., Takeda Y., Hori M., Yamamoto K. Difference of clinical characteristics between hypertensive patients with and without diastolic heart failure: role of diastolic dysfunction and renal insufficiency. Hypertens Res 2008, 31:1865-1872.
13. Takeda Y., Sakata Y., Mano T., Ohtani T., Kamimura D., Tamaki S., Omori Y., Tsukamoto Y., Aizawa Y., Komuro I., Yamamoto K. Competing risks of heart failure with preserved ejection fraction in diabetic patients. Eur J Heart Fail 2011, 13:664-669.
14. Casas-Vara A., Santolaria F., Fernandez-Bereciartua A., Gonzalez-Reimers E., Garcia-Ochoa A., Martinez-Riera A. The obesity paradox in elderly patients with heart failure: analysis of nutritional status. Nutrition 2012, 28:616-622.
15. Kinugasa Y., Kato M., Sugihara S., Hirai M., Yamada K., Yanagihara K., Yamamoto K. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 2013, 77:705-711.
16. McAlister F.A., Wiebe N., Ezekowitz J.A., Leung A.A., Armstrong P.W. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009, 150:784-794.
17. Swedberg K., Komajda M., Bohm M., Borer J.S., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
18. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:807-816.
19. Lechat P., Hulot J.S., Escolano S., Mallet A., Leizorovicz A., Werhlen-Grandjean M., Pochmalicki G., Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001, 103:1428-1433.
20. Appleton C.P., Galloway J.M., Gonzalez M.S., Gaballa M., Basnight M.A. Estimation of left ventricular filling pressures using two-dimensional and Doppler echocardiography in adult patients with cardiac disease. Additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction. J Am Coll Cardiol 1993, 22:1972-1982.
21. Pritchett A.M., Mahoney D.W., Jacobsen S.J., Rodeheffer R.J., Karon B.L., Redfield M.M. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol 2005, 45:87-92.
22. Yamaguchi H., Yoshida J., Yamamoto K., Sakata Y., Mano T., Akehi N., Hori M., Lim Y.J., Mishima M., Masuyama T. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004, 43:55-60.
23. Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., Marino P., Smiseth O.A., De Keulenaer G., Leite-Moreira A.F., Borbely A., Edes I., Handoko M.L., Heymans S., Pezzali N., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
24. Hamaguchi S., Kinugawa S., Goto D., Tsuchihashi-Makaya M., Yokota T., Yamada S., Yokoshiki H., Takeshita A., Tsutsui H. Predictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with heart failure - a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2011, 75:2403-2410.
25. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
26. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
27. Giugliano D., Acampora R., Marfella R., De Rosa N., Ziccardi P., Ragone R., De Angelis L., D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997, 126:955-959.
28. Badve S.V., Roberts M.A., Hawley C.M., Cass A., Garg A.X., Krum H., Tonkin A., Perkovic V. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2011, 58:1152-1161.
29. Henkel D.M., Redfield M.M., Weston S.A., Gerber Y., Roger V.L. Death in heart failure: a community perspective. Circ Heart Fail 2008, 1:91-97.
30. Zile M.R., Gaasch W.H., Anand I.S., Haass M., Little W.C., Miller A.B., Lopez-Sendon J., Teerlink J.R., White M., McMurray J.J., Komajda M., McKelvie R., Ptaszynska A., Hetzel S.J., Massie B.M., et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010, 121:1393-1405.